Crescent Biopharma vs Pyxis Oncology
CBIO and PYXS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CBIO and PYXS compare
Crescent Biopharma is the larger company, worth 3.3 times as much as Pyxis Oncology ($501M against $151M).
Crescent Biopharma scores higher on the StockData Score (7 against 5 for Pyxis Oncology), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CBIO | PYXS |
|---|---|---|
| Size and price | ||
| Market cap | $501M | $151M |
| Share price | $13.48 | $1.81 |
| Change, 1 year | 7.8% | −45.3% |
| Change, 5 years | −93.2% | −85.0% |
| Beta (5Y) | 1.64 | 1.62 |
| Employees | 44 | 56 |
| StockData Score | ||
| Total score | 7 (better) | 5 |
| Valuation score | 0 | 0 |
| Growth score | 1 (better) | 0 |
| Performance score | 0 | 0 |
| Health score | 6 (better) | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | 3.1× (better) | 13.2× |
| FCF yield | −14.7% | – |
| Growth | ||
| Revenue growth, 5Y average | 1.3% | – |
| Profitability | ||
| Return on equity | −63.5% (better) | −179% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 9.66 (better) | 1.34 |
| Altman Z-score | 11.73 (better) | −15.78 |
| Piotroski F-score | – | 1 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 79.7% | 40.9% |
| Held by insiders | 38.6% | 20.4% |
| Insider net buying, 12 months | $29.1M (better) | −$107K |
| Short interest, % of float | 21.0% | 7.4% |
Go deeper
- CBIO stock overview
- CBIO income statement
- CBIO valuation and score
- PYXS stock overview
- PYXS income statement
- PYXS valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.